Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06581575 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
A Phase 2 study of Shingles and Infectious Diseases, sponsored by Immorna Biotherapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 467
- Enrollment target
- 8
- Study locations
NCT06581575 is a Phase 2 study of Shingles and Infectious Diseases that is active but no longer recruiting, run by Immorna Biotherapeutics. The registered enrollment target is 467 participants, above the 321-participant average among 6 other Shingles trials with a reported enrollment target (45% higher). The trial reports 8 study locations across 7 states.
The verdict
NCT06581575, a Phase 2 study of Shingles and Infectious Diseases, is active but no longer recruiting, sponsored by Immorna Biotherapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 467 participants
- Enrollment target
- 8
- Study locations
Study Summary
The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles). Subjects will be randomized to receive either JCXH-105 or Shingrix.
Conditions Studied
Interventions
- BIOLOGICAL Shingrix
- BIOLOGICAL JCXH-105
Study Locations (8)
Texas
- Delricht Research - Prosper
- DM Clinical Research - Sugarland - Sugar Land
Arizona
- Noble Clinical Research - Tucson
California
- Long Beach Research Institute - Long Beach
Illinois
- DM Clinical Research - Chicago - Chicago
Nebraska
- Quality Clinical Research - Omaha
New Jersey
- DM Clinical Research - New Jersey - Jersey City
South Carolina
- Delricht Research - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 467 participants |
| Start Date | 2024-10-16 |
| Est. Completion | 2025-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06581575
The ClinicalTrials.gov registry entry for NCT06581575 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 467 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 321-participant average among 6 other Shingles trials with a reported enrollment target (45% higher). The listed sponsor is Immorna Biotherapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Shingles appearing as the primary indexed condition, and to 2 interventions - of which Shingrix is the first listed.
NCT06581575 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Texas, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06581575 about?
NCT06581575 is a clinical study titled "A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine". The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles). Subjects will be randomized to receive either JCXH-105 or Shingrix.
What is the current status of trial NCT06581575?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 467 participants. The study started on 2024-10-16. Estimated completion is 2025-08.
What conditions does trial NCT06581575 study?
This clinical trial studies the following conditions: Shingles, Infectious Diseases, Herpes Zoster (HZ).
What interventions are being tested in trial NCT06581575?
The interventions under investigation include: Shingrix (BIOLOGICAL), JCXH-105 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06581575?
This trial is sponsored by Immorna Biotherapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06581575 being conducted?
This trial has 8 study locations across Arizona, California, Illinois, Nebraska, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Shingles
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
RECRUITING · Phase 2
-
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
ACTIVE NOT RECRUITING · Phase 2
-
Systems Biology of Zoster Vaccine
COMPLETED · Phase 2
-
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
COMPLETED · Phase 1
-
Valacyclovir in Immunocompromised Children
COMPLETED · Phase 1
-
A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.